MarketBeat
14 Sept 2026, 08:02 UTC · 2h ago
Verdict
Headline takes no side. We score EXEL +0.80 across five claims.
Our read: bullish.
EXEL score
+0.80
More positive than 88% of ticker scores this week
Price reaction
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
Analysis by Kasper Rasmussen
What the story claims
5 claims · scored −1 bearish … +1 bullish
Exelixis is awaiting a regulatory decision for zanzalintinib in third-line metastatic colorectal cancer, a market the company estimates at $1.5 billion.
More positive than 98% of claims this week
Exelixis estimates the total addressable market for zanzalintinib across its current studies to be approximately $5 billion.
So whatThis provides a high-ceiling valuation for the company's growth beyond its current lead product.
Continue reading
5 related stories
Search tags
More positive than 91% of claims this week
CABOMETYX increased its market share in renal cell carcinoma (RCC) to 47% in Q2 2026 from 45% a year prior.
More positive than 77% of claims this week
The company expects to keep annual R&D expenses at or below $1 billion for the foreseeable future while maintaining a $750 million share repurchase program.
So whatFiscal discipline and capital returns to shareholders provide a floor for the stock price and protect operating margins.
More positive than 66% of claims this week
CABOMETYX holds a 45% share of new patients in second-line neuroendocrine tumors (NET), with a total addressable market estimated at $1 billion.
More positive than 55% of claims this week
Which stocks this story touches
More positive than 88% of ticker scores this week
The company reports market share gains for CABOMETYX, a strong pipeline including zanzalintinib, and a disciplined capital allocation strategy.
More positive than 54% of ticker scores this week
The company is partnered with Exelixis on promising combination studies for clear cell RCC.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Business Wire
10h ago
Price reaction
Expected +0.80Actual —
EXEL hasn't traded since this ran. Last close $56.12 (Sep 11); the reaction starts at the next open.
EXEL chart →
